Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

Perspective Therapeutics, Inc. announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans.